Las evidencias de cada alternativa | 03 ABR 20

Intervenciones globales no farmacológicas en la pandemia COVID-19

En ausencia de una vacuna COVID-19, evaluamos el papel potencial de una serie de medidas globales de salud pública, llamadas intervenciones no farmacéuticas: mitigación y supresión
Autor/a: Dr. Gustavo Ontiveros y Dr. Scatularo C. Emmanuel Fuente: IntraMed 
INDICE:  1. Texto principal | 2. Referencias bibliográficas
Referencias bibliográficas
1. Bootsma MCJ, Ferguson NM. The effect of public health measures on the 1918 influenza pandemic in U.S. cities. Proc Natl Acad Sci U S A 2007;104(18):7588–93.
2. Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. Comment How will country based mitigation measures influence the course of the COVID-19 epidemic? 2020;2019(20):1– 4.
3. The Coalition for Epidemic Preparedness Innovations. CEPI welcomes UK Government’s funding and highlights need for $2 billion to develop a vaccine against COVID-19 [Internet]. 2020;Available from:
4. World Health Organisation. Pandemic influenza A (H1N1) 2009 virus vaccine – conclusions and recommendations from the october 2009 meeting of the immunization Strategic Advisory Group of experts. Wkly Epidemiol Rec 2009;84(49):509–16.
5. Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature 2006;442(7101):448–52.
6. Halloran ME, Ferguson NM, Eubank S, et al. Modeling targeted layered containment of an influenza pandemic in the United States. Proc Natl Acad Sci U S A 2008;105(12):4639–44.
7. Ferguson NM, Cummings DAT, Cauchemez S, et al. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 2005;437(7056):209–14.
8. Mossong J, Hens N, Jit M, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008;5(3):0381–91.
9. Linton NM, Kobayashi T, Yang Y, et al. Epidemiological characteristics of novel coronavirus infection: A statistical analysis of publicly available case data. medRxiv [Internet] 2020 [cited 2020 Feb 18];2020.01.26.20018754. Available from:
10. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus– Infected Pneumonia. N Engl J Med 2020.
11. Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill 2020;25(4):1–5.
12. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of COVID-19 disease. medRxiv 2020; Available from
13. Gaythorpe K, Imai N, Cuomo-Dannenburg G, et al. Report 8: Symptom progression of 2019 novel coronavirus [Internet]. 2020. Available from:
14. Ostermann H, Blasi F, Medina J, Pascual E, McBride K, Garau J. Resource use in patients hospitalized with complicated skin and soft tissue infections in Europe and analysis of vulnerable groups: The REACH study. J Med Econ 2014;17(10):719–29.
15. Kucharski AJ, Russell TW, Diamond C, et al. Early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Infect Dis [Internet] 2020;3099(20):2020.01.31.20019901. Available from:
16. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 2020.
17. Seth Flaxman, Swapnil Mishra, Axel Gandy et al. Estimating the number of infections and the impact of non-pharmaceutical interventions on COVID-19 in 11 European countries. Imperial College London (2020), doi:
18. Katharina Fenz and Homi Kharas.


Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí

Contenidos relacionados
Los editores le recomiendan continuar con las siguientes lecturas: